亞盛醫藥-B(06855.HK)擬向葉長青等三名董事各授出9418份受限制股份單位
格隆匯7月14日丨亞盛醫藥-B(06855.HK)宣佈,於2021年7月13日,公司建議待獨立股東於股東特別大會批准後,根據受限制股份單位計劃向葉長青、尹正及任為(各自為一名公司獨立非執行董事)授出合共9,418份、9,418份及9,418份受限制股份單位(相當於9,418股、9,418股及9,418股股份)。
根據聯交所於2021年7月13日(即建議向葉長青、尹正及任為各自授出受限制股份單位的日期)所報收市價49.50港元計算,將向葉先生、尹博士及任先生各自授出的受限制股份單位涉及的相關股份總市值為1,398,573港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.